June 7, 2012
RIKEN and the National Cancer Center (NCC) have announced that they have succeeded in visualizing the kinetics of the molecular targeted drug trastuzumab (brand name: Herceptin), administered to patients with breast cancer, using positron emission tomography (PET). The new technique...read more